West Pharmaceutical Services, Inc. (WST)
US — Healthcare Sector
Automate Your Wheel Strategy on WST
With Tiblio's Option Bot, you can configure your own wheel strategy including WST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol WST
- Rev/Share 39.9407
- Book/Share 37.0083
- PB 5.9576
- Debt/Equity 0.113
- CurrentRatio 2.7672
- ROIC 0.1441
- MktCap 15840473792.0
- FreeCF/Share 4.2331
- PFCF 51.6144
- PE 34.214
- Debt/Assets 0.0838
- DivYield 0.0038
- ROE 0.1747
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | WST | Barclays | -- | Equal Weight | -- | $245 | June 24, 2025 |
| Initiation | WST | Evercore ISI | -- | Outperform | -- | $275 | March 18, 2025 |
| Upgrade | WST | Deutsche Bank | Hold | Buy | -- | $250 | Feb. 14, 2025 |
| Initiation | WST | Citigroup | -- | Buy | -- | $400 | Jan. 8, 2025 |
| Initiation | WST | Wolfe Research | -- | Peer Perform | -- | -- | Dec. 13, 2024 |
| Upgrade | WST | UBS | Neutral | Buy | $350 | $390 | Dec. 12, 2024 |
News
West Announces Fourth-Quarter and Full-Year 2024 Results
WST
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.
Read More
Will Segmental Performance Drive West Pharmaceutical's Q4 Earnings?
WST
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
West Pharmaceutical Services WST is scheduled to release fourth-quarter 2024 results on Feb. 13, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 22.52%.
Read More
About West Pharmaceutical Services, Inc. (WST)
- IPO Date 1980-03-17
- Website https://www.westpharma.com
- Industry Medical - Instruments & Supplies
- CEO Eric M. Green
- Employees 10600
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.